The Prof G Pod – Scott Galloway (5 mentions) reports on the company's stock performance and warns of declining sales, contrasting Novo Nordisk with the success of Eli Lilly, as mentioned in "Why is Eli Lilly seeing surging sales as obesity rival Novo Nordisk plummets?"
Novo Nordisk is a Danish multinational pharmaceutical company focused on diabetes and obesity care. The company faces market volatility, demonstrated by an 18% stock collapse reported by The Prof G Pod – Scott Galloway, despite its leading position. Its experimental drug, CagriSema, underperformed against Eli Lilly's tirzepatide in trials.
The obesity drug market is no longer a guaranteed win for every player. While Eli Lilly continues to surge, Novo Nordisk is grappling with an 18% stock crash and systemic revenue degradation. A combination of regulatory intervention and internal shifts toward lower-priced oral therapies has created a perfect storm for the Danish pharmaceutical giant.
Modern weight loss drugs are doing more than shrinking waistlines; they are stripping away the emotional armor many have used to survive for decades. When food no longer provides comfort, the underlying psychological triggers are forced into the light, creating a high-stakes battle between physical health and mental stability.
